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Abstract — Introduction: Novel Psychoactive Substances (NPSs) are often sold online as “legal” and
“safer” alternatives to International Controlled Drugs (ICDs) with captivating marketing strategies. Our
aim was to review and summarize such strategies in terms of the appearance of the products, the brand
names, and the latest trends in the illicit online marketplaces. Methods: Scientific data were searched
in PsychInfo and Pubmed databases; results were integrated with an extensive monitoring of Internet
(websites, online shops, chat rooms, fora, social networks) and media sources in nine languages
(English, French, Farsi, Portuguese, Arabic, Russian, Spanish, and Chinese simplified/traditional)
available from secure databases of the Global Public Health Intelligence Network. Results: Evolving
strategies for the online diffusion and the retail of NPSs have been identified, including discounts
and periodic offers on chosen products. Advertisements and new brand names have been designed to
attract customers, especially young people. An increased number of retailers have been recorded as
well as new Web platforms and privacy systems. Discussion: NPSs represent an unprecedented chal-
lenge in the field of public health with social, cultural, legal, and political implications. Web monitoring
activities are essential for mapping the diffusion of NPSs and for supporting innovative Web-based
prevention programmes.
Keywords — brand names, Internet monitoring, legal highs, marketing, novel psychoactive
substances, PIEDs
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INTRODUCTION
Novel Psychoactive Substances (NPSs), also known
as “designer drugs,” “herbal highs,” “research chemicals,”
and “legal highs,” comprise an ever-increasing number of
“chemical,” pharmaceutical, and herbal drugs often adver-
tised as “legal” and “safer” alternatives to International
Controlled Drugs (ICDs) (Corazza et al. 2013). NPSs
may share with ICDs common ways of consumption (e.g.,
ingestion, inhalation, injection) and pharmacological prop-
erties, but they are often more powerful and harmful
(Vardakou et al. 2010).
While the use of ICDs seems to have stabilized over
the past decades (EMCDDA 2013), the market of NPSs has
significantly grown (INCB 2013), representing an unprece-
dented challenge in the field of global public health. The
international drug control system is floundering, for the first
time, under the spread of this new phenomenon; the EU
Early Warning System (EWS) of the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) has
officially reported the appearance of 24 NPSs in 2009,
41 in 2010, 49 in 2011, and 73 in 2012 (EMCDDA
2013).
According to the World Drug Report 2013 of the
United Nations Office on Drugs and Crime, the rapid diffu-
sion of NPSs is widespread in 70 countries and territories.
For instance, excluding cannabis, in the US the use of NPSs
among students is more widespread than the use of any
other drug and appears to be more than twice as widespread
as in the European Union (UNODC 2013). Within Europe,
Eurobarometer data suggest that five countries account for
almost three-quarters of all users of NPSs: United Kingdom
(23% of the European Union total), followed by Poland
(17%), France (14%), Germany (12%), and Spain (8%)
(Eurobarometer 2011). Overall, close to 5% of people aged
15-24 (2.9 million people) have already experimented with
NPSs in the European Union, which is equivalent to one-
fifth of the numbers who have tried cannabis and close to
around half of the number who have used drugs other than
cannabis. The emergence of NPSs has also been reported in
East Asia, the Middle East, Oceania, South America, and
several African countries (UNODC 2013).
Over the past few years, there has been increas-
ing recognition from the EMCDDA (2013), International
Narcotics Control Board (INCB 2013), governments and
international regulatory bodies (e.g., ACMD 2011), the sci-
entific community (Butler et al. 2007; Cone 2006; Hoover
et al. 2008; Schifano et al. 2009; Corazza et al. 2012),
as well as the public and media (e.g., Bruno, Poesiat &
Matthews 2013) of the major role that the Internet is now
playing in shaping the recreational NPSs market. Various
surveys and studies have shown that the Internet is the
most popular source of information about illicit drugs and
their use and that this information is often biased and
potentially inaccurate (Schifano et al. 2006; Deluca et al.
2012; Corazza et al. 2014a). In this rapid change of drug
scenarios, the Internet seems to play a central role in the
NPSs business more than it does in the illicit ICDs business
(INCB 2013; Bersani et al. 2014).
The number of online shops offering NPSs products
for sale in European Union countries increased from 170 in
January 2010 to 314 in January 2011 and 693 in January
2012 (EMCDDA 2012). The characteristics of the websites
selling these products (e.g., access 24 hours a day, a virtu-
ally unlimited number of products available, privacy guar-
anteed both to retailers and customers, periodic discounts
and alerts on new items) provide a constant dynamism of
the market with daily new products and advertisements.
The competitive conditions of a substantially unregulated
market have led to more aggressive advertising campaigns
among NPSs online retailers in order to attract a larger
number of customers who may be easily manipulated by
misleading and false claims (Archer, Treble & Williams
2011).
The aim of the present manuscript was to review and
summarize some aspects of the strategies adopted by online
NPSs retailers: (1) the appearance of the products; (2) the
brand names; and (3) the latest trends in the illicit online
marketplaces.
METHODS
The literature on NPSs online marketing strategies was
searched in PsychInfo and Pubmed databases. Considering
the limited peer-reviewed data, results were integrated
with an extensive and regular monitoring of the Internet
(i.e., websites, online shops, chat rooms, newsgroups, fora,
eBay, YouTube, Facebook, Twitter, Google Insights for
Search) carried out in four languages (English, German,
Spanish, Italian) with respect to NPSs online marketing
strategies. More than 100 websites were monitored on a
regular basis, depending on relevance. A list of 20 key
resources monitored is reported in Table 1.
Additional searches were carried out in the database
provided by the Global Public Health Intelligence Network
(GPHIN). This is a secure, Internet-based early warning
system that gathers preliminary reports of public health
significance by monitoring global media sources in near
“real-time,” 24 hours a day, seven days a week. GPHIN
is developed by Canada’s Public Health Agency, and is
part of the World Health Organization’s (WHO) Global
Outbreak and Alert Response Network (GOARN); it mon-
itors news sources and websites across the globe in nine
languages (e.g., English, French, Farsi, Portuguese, Arabic,
Russian, Spanish, and Chinese simplified/traditional)
(Keller et al. 2009). Permission for the study was granted
by the School of Pharmacy Ethics Committee, University
of Hertfordshire, Hatfield, UK (November 2013;
PHAEC/10-42).
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TABLE 1
List of 20 Key Resources
Name Country/Language Web address Type of resource
Drugs-forum International/English www.drugs-forum.com Open Forum
Bluelight International/English www.bluelight.ru Open Forum
Legal Highs Forum International/English www.legalhighsforum.com Open Forum
Cannabis café Spanish www.cannabiscafe.net Open Forum
Energy Control Spanish www.energycontrol.org Open Forum
Overgrow-italy Italian www.overgrow-italy.nl Open Forum
Shroomery International/English www.shroomery.org Open Forum
Partyvibe International/ English www.partyvibe.com Open Forum
Hipforums International/English www.hipforums.com/newforums Open Forum
Reddit International/English www.reddit.com/r/drugs Open Forum
Zoklet International/English www.zoklet.net Open Forum
Tripme International/English www.tripme.co.nz Open Forum
Opiophile International/English www.opiophile.org Open Forum
Erowid International/English www.erowid.org Open Forum
Psychonaut International/sections in six
different languages
www.psychonaut.com Open Forum
Ice Headshop International/English www.iceheadshop.co.uk Online pharmacy
UKhighs International/English www.ukhighs.com Online pharmacy
Neorganics International/English www.neorganics.net Online pharmacy
Azarius International/sections in six
different languages
www.azarius.net Online pharmacy
Am-Hi-Co International/English www.am-hi-co.co.uk Online pharmacy
These sites are still available.
RESULTS
Appearance of NPSs and Packaging
The main feature of online marketing strategies devel-
oped by NPSs retailers is to present the advertised products
as legal and safer alternatives to traditional ICDs (Corazza
et al. 2012; Bersani et al. 2002). By doing so, the poten-
tial risks associated with the consumption of NPSs are
minimized and the presence of psychoactive ingredients
is often disguised by not being listed on the packag-
ing (Schifano et al. 2009). Products are often advertised
online as “something else” (e.g., “herbal mixtures,” “party
pills,” “bath salts,” “incenses,” “fruit jakes,” “Halloween
candies,” “fertilizers,” “perfumes,” “pound cleaners”), and
thus are less noticeable as drugs (Corazza et al. 2014a).
Moreover, the explicit references to their legality affect
the users’ perception on the real content. In fact, the idea
that legality can equate with safety still remains a common
misbelief amongst some recreational users (Corazza et al.
2011).
As in the case of “Spice drugs” (Schifano et al.
2009), herbal compounds are frequently sold in color-
ful packages designed to appeal to vulnerable consumers,
mainly adolescents and young adults. Compounds sold
as pills, in addition to a variety of colors, are often
characterized by particular imprints; trademarks like Louis
Vuitton, Facebook, Sky, Apple, Rolex, McDonald’s, and
Mitsubishi have been found (Kraner et al. 2001). Some
of these have given inspiration for new brand names such
as “Green Rolex,” “Green Apple,” “Pink McDonald’s,”
or “Red Mitsubishi.” These pills mainly contain the
empathogenic substance MDMA (3,4-methylenedioxy-N-
methylamphetamine; “Ecstasy”) or PMA (para-methoxy-
amphetamine). PMA is a serotonergic substance of the
amphetamine class, with psychedelic and antidepressant
properties; it first came into circulation in the early 1970s,
when it was used as an alternative to LSD for its hal-
lucinogenic effects. Since the 1970s, it has caused more
than 90 deaths in Canada, the US, Australia, and Europe
(Vevelstad et al. 2012), mostly related to the consequences
of acute temperature elevation (hypertemia) leading to
multi-organ failure occurring at dosages only slightly above
the usual recreational range.
In the case of NPSs sold as powders, the term “bath
salts” is frequently used in order to give the appear-
ance of legality, taking inspiration from the white crystals
often resembling bathing products; they are also some-
times called “jewelry cleaners,” “plant foods,” or “phone
screen cleaner.” Usually, these substances contain synthetic
cathinones, such as mephedrone, whose psychostimulant
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effects are similar to cocaine and amphetamines. Diffusion
of mephedrone has reached extremely high levels of pop-
ularity among clubbers (Wood, Greene & Dargan 2011)
and its abuse is secondary only to cocaine. The popular-
ity of mephedrone has been associated with a decreasing
availability/purity of both MDMA and cocaine (Schifano
et al. 2011). Mephedrone has been implicated in a num-
ber of deaths, especially in the UK, and in 2010 it was
banned in several European countries (Mas-Morey et al.
2013).
NPSs Brand Names
A comprehensive analysis of more than 1,000 brand
names used to advertise NPSs online has been carried out
(Table 2). To our knowledge, this is the most extensive
overview of NPSs brand names; however, some limitations
related to the extreme volatility of the online market should
be highlighted: (1) NPSs are rapidly re-branded; (2) a sin-
gle brand name often identifies different NPSs in different
countries; and (3) often a single brand name identifies var-
ious NPSs in different times (Ramsey et al. 2010; Davies
et al. 2010). Therefore, the collected data do not allow a
statistical analysis aimed at investigating selection criteria
of the brand names.
Overall, neither the broad categories nor the brand
names are representative of the actual contents of the prod-
ucts (Brandt et al. 2010). The present research suggests
that the strategies of choice of brand names are carefully
designed to attract customers, especially teenagers, mini-
mizing the possible risks derived from their consumption
and maximizing the wanted “highs.” In this context, names
referring to popular movies, comics, animals, or landscapes
are frequently used (see Table 3).
In relation to movies, the brand “Black Mamba,”
referring to the character interpreted by Uma Thurman in
Quentin Tarantino’s Kill Bill, has become very popular
among young people (Musshoff et al. 2014). This product
contains the synthetic cannabinoid AM-2201, and it was
banned in 2013 in various countries (Lesiak et al. 2013);
as a result of the ban, related cannabimimetic drugs such
as 5F-AKB48, rebranded as “Clockwork Orange” in ref-
erence to Stanley Kubrick’s movie, have recently reached
equal popularity (Drug Enforcement Administration 2013).
In relation to cinema, the NPS “Mad Alice” recalls
Alice in Wonderland and the NPS “Charlie Sheen” refers
to the famous American actor. “Mad Alice” is an herbal
blend containing Turnera Diffusa (Estrada-Reyes et al.
2009) and Lactuca Virosa (Besharat, Besharat & Jabbari
2009) with aphrodisiac and psychedelic properties; the
product “Charlie Sheen” initially contained the syn-
thetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)
and, since 2012, the psycho-stimulants methiopropamine
and ethylphenidate (Welter et al. 2013; Zhu, Patrick &
Markowitz 2011).
Among the brand names related to comics, refer-
ences to characters from Marvel and DC comics have been
recorded. For instance, the products called “Krypton” and
“Kryptonite” emerged from our searches. “Krypton” stands
for the opiod O-Desmethyltramadol (O-DT) (Arndt et al.
2011), linked to various fatalities from overdose during
2010–2011 (Kronstrand et al. 2011). On the other hand,
“Kryptonite” can contain both synthetic cannabinoids or
lysergic acid amide (LSA), a compound closely related
TABLE 2
Substances and Brand Names Identified by Monitoring Scientific (PubMed and PsychInfo) Databases and
Online and Media Reports
Class Examples
No. substances identified
(=650)
No. brand names identified
(=1074)
PIA-related compounds MDMA-like drugs 179 156
Synthetic cannabimimetics Spice drugs 220 490
Cathinones Mephedrone, MDPV 30 67
Tryptamines 5-Meo-DALT 66 18
Psychedelic Phenethylamines
(from Shulgin Index)
5-APB, 6-APB 126 94
GHB-like GHB, GBL 3 18
PCP-like MXE, PCE 5 47
Piperazines m-BZP 2 25
Herbal plants Salvia Divinorum 6 52
Medicines Pregabalin, Opioids 13 107
Abbreviations: PIA, Para-iodo-amphetamine; MDMA, 3,4-methylenedioxy-N-methamfetamine; 4-MMC, mephedrone; MDPV, methylenedioxypy-
rovalerone; Meo-DALT N,N-dialyl-5-methoxytryptamine; 5APB, 5-(2-aminopropyl)benzofuran; 6APB, 6-(2-aminopropyl)benzofuran; GBL,
g-butyrolactone;1,4-BD, 1,4-butanediol; PCE, N-ethyl-1-phenylcyclohexylamine; MXE, methoxetamine; MBZP, methylbenzylpiperazine.
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TABLE 3
Examples of NPSs Brand Names
NPSs names with reference to movies
Brand Name
Pharmacological
name Class
Black mamba AM-2201 Syn. Cannabinoid
Clockwork
orange
AKB48 Syn. cannabinoid
Flatliners 4-MTA PIA rel. compound
Pink Panther MDAI/5-IAI PIA rel. compound
Charlie
Sheen
MPA/EP PIA rel. compound
Fantasia DMT Tryptamine
Scarface MDPV Sub. cathinone
Bounce 4-MMC Sub. cathinone
Vanilla Sky 2-DPMP Sub. cathinone
Mad Alice T.diffusa/L.virosa Plant
NPSs names with reference to comics
Scooby snax AM-694 Syn. cannabinoid
Venom AM-2201 Syn. cannabinoid
Kryptonite JWH-018 Syn. cannabinoid
Black Widow JWH-018 PIA rel. compound
Dr Death PMA PIA rel. compound
Green Goblin 5-APB PIA rel. compound
Dennis the
Menace
MDMA PIA rel. compound
Sparkle Plenty DMAA Psy.Phenethylamine
He-Man 5-IT Tryptamine
Krypton O-DT Medicinal product
NPSs names with reference to animals
Magic Dragon AKB48 Syn. cannabinoid
King Cobra JWH-018 Syn. cannabinoid
Wolf Pack JWH-122 Syn. cannabinoid
Dragonfly Bromodragonfly Psy. Phenethylamine
Chicken
yellow
PMA PIA rel. compound
Woof Woof MDAI PIA rel. compound
Meow Meow 4-MMC Sub. cathinone
Snow Leopard MDPV Sub. cathinone
White Horse MDPV Sub. cathinone
Elephant 5-MeO-DMT PCP-like
NPSs names with reference to landscapes/space
Yucatan fire JWH-073 Syn. cannabinoid
K2 JWH-018 Syn. cannabinoid
Moon rocks JWH-018 Syn. cannabinoid
Storm DMAA Psy.Phenethylamine
Ocean snow PMMA PIA rel. compound
Seventh
Heaven
2C Tryptamine
Space Trip TFMPP Piperazine
Rainbows m-BZP Piperazine
Lunar Wave MDPV Sub. Cathinone
Eclipse Salvia Plant
(Continued)
TABLE 3
(Continued)
NPSs names with reference to the expected psychotropic
effects
Dr. Feel Good JWH-018 Synthetic
cannabinoid
Mr Nice Guy JWH-018 Synthetic
cannabinoid
45 minutes-
Psychosis
DMT Tryptamine
Tripstasy 2C Tryptamine
Liquid Ecstasy GHB GHB-like
Lover’s speed MDMA PIA related
compound
Mr Happy Methylone Substitute cathinone
Bliss 4-MMC Substitute cathinone
Magic mint Salvia divinorum Plant
Seven monther Tropicamide Medicinal product
Abbreviations: 4-MTA, 4-Methylthioamphetamine; MDAI, 5,6-
Methylenedioxy-2-aminoindane; MPA, Methiopropamine; EP,
ethylphenidate; DMT, N,N-Dimethyltryptamine; 2-DPMP, 2-
diphenylmethylpiperidine; PMA, para-methoxy-amphetamine;
DMAA, 1,3-dimethylamylamine; PMMA, paramethoxymetham-
phetamine; TFMPP, 3-Trifluoromethylphenylpiperazine; m-BZP,
methylbenzylpiperazine.
to lysergic acid diethylamide (LSD); in this latter case,
retailers advice customers to “Keep Kryptonite out of reach
of children and Superman!” (Azarius online smartshop
2013).
In relation to animals, the brands include “Meow
Meow” and “Woof Woof.” “Meow Meow” refers to
mephedrone (Wood et al. 2012). Conversely, “Woof Woof”
refers to 5,6-Methylenedioxy-2-aminoindane (MDAI), a
substance with entactogenic properties. When mephedrone
was banned in the UK in April 2010, MDAI was intro-
duced to the market as a legal and safe alternative to “Meow
Meow” (Gallagher et al. 2012); in the UK, three deaths
involving MDAI in 2011 and 2012 have been reported
(Corkery et al. 2013).
Brand names related to landscapes (e.g., “K2,”
“Yucatan fire”) and space (e.g., “Moon rocks,” “Lunar
wave”) are also common. Others include brand names
referring to the expected psychedelic effects of chosen
products (e.g., “Dr. Feel good,” “Lover’s speed”) or to
specific side-effects, as in the case of “Seven Monther,”
a brand name for Tropicamide eye drops, indicating “the
amount of time (e.g., seven months) that it takes to kill”
(Bersani et al. 2013).
Evolution of the NPSs Online Marketplaces
Although NPSs can be available at local head shops,
the Internet plays a crucial role in the distribution of these
Journal of Psychoactive Drugs 291 Volume 46 (4), September – October 2014
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products. This has become a highly profitable business, as
it provides a number of advantages, including vast pools
of customers, swift and easy operational management, and
anonymity, while overcoming national and international
legislations (Hughes & Winstock 2012). Businesses are
advertised on websites, YouTube videos, social networks
(Instagram, Facebook, Twitter), as well as drug fora, which
are crucial for the exchange of information and promotion
of the latest products (Walsh 2011; Lange et al. 2010).
Alerts on the latest deals are often sent via SMS and
E-mails to non-registered users (Davey et al. 2012). Among
the most popular websites, Silk Road deserves the name
“Amazon.com of illegal drugs” or “eBay for drugs” (Hout
& Bingham 2013; Barratt 2012). Until it was seized and
shut down by the Federal Bureau of Investigation (FBI) in
October 2013 (Konrad 2013), it operated as a Tor hidden
service for the distribution of ICDs as well as NPSs, but
also child pornography, stolen credit cards, and weapons
(Dasgupta et al. 2013). It has been estimated that approx-
imately 220 distinct categories of illicit drugs were sold
on this website (Hout & Bingham 2013). These were able
to generate annual sales worth $22 million (£14.5million),
Forbes has reported (Greenberg 2012).
However, the largest business we were able to identify
so far is related to Performance and Imaging Enhancing
Drugs (PIEDs), an umbrella term used to describe a variety
of substances taken to enhance human abilities and capabil-
ities. More specifically, PIED drugs include: (1) anabolic
drugs such as steroid supplements, used to enhance mus-
cle growth, which were very popular among athletes in the
1980s; (2) opioid analgesic drugs (e.g., codeine, tramadol),
which are used for pain relief and as muscle relaxants;
(3) image-enhancing drugs taken to change weight, skin
coloration, promote/stop hair loss, as well as a variety of
beauty and anti-aging products; (4) cognitive enhancers
(e.g., adderall, modafinil, piracetam); (5) products labelled
as sleep inducers and antidepressant drugs, including pre-
scription drugs (such as benzodiazepines); (6) “sex drugs”
and aphrodisiacs, which include prescription drugs (e.g.,
sildenafil) (Evans-Brown et al. 2012; Corazza et al. 2014b).
Illicit manufacturers and retailers have developed spe-
cific marketing strategies to sell these products, including
prescription medicines, via Online Pharmacies (OPs) at
discounted prices and without prescription (Corazza et al.
2013). In fact, OPs are able to attract a wider range of cus-
tomers who remain unaware that the products could contain
untested or illicit substances (Evans-Brown et al. 2012;
Corazza et al. 2014b).
Cultural differences on the ways these products are
advertised online have also emerged from our searches.
For instance, Bigdeli et al. have recently shown how NPSs
in Iran and the Middle East are available in occult and
concealed manners on public and legal websites such as
those for real estate or general supplies (Bigdeli et al.
2013).
DISCUSSION
The Internet represents an integral part of daily life.
Far from being merely a virtual place for information
exchange, as conceived originally, it has become a means
for accessing services and goods via “e-commerce” (Gelatti
et al. 2013). The sale of NPSs has not been excluded from
this revolution.
In this context of sudden change, a major challenge
remains the lack of reliable scientific evidence, which
develops too slowly in comparison with the rapid evolution
of the drug scenario; in other words, the business-driven
NPSs online market is by far more rapid than scientific
research. For this reason, Web-based activities represent a
prompt response for a better understanding of new ongo-
ing drug trends as well as the provision of preliminary
information to professionals working in the field and mem-
bers of the general public (Deluca et al. 2012). Further, as
has recently been demonstrated by the European-Union-
funded ReDNet project (Corazza et al. 2013), it is cru-
cial that prevention strategies include health messages to
users/potential users via online information and commu-
nication technologies (ICTs). Consistent with this idea,
Ridout & Campbell (2014) have recently performed a
study where Facebook was used to deliver positive mes-
sages about safe alcohol use to students, and Free et al.
(2010) summarized the evidence for the effectiveness of
mobile Web technology interventions for improving health
outcomes around the world.
The present article covers some specific aspects asso-
ciated with the diffusion of the NPSs, and further studies
are required. The main limitation of our investigation is
intrinsic to the nature of the Internet and the Web sources
monitored: the information available online is continuously
changing, and our data refer to products which were avail-
able until December 2013. It is suggested that monitoring
activities should be continued; that more countries, lan-
guages, resources, researchers, and health professionals
should be involved; and that the findings should be widely
shared with public health agencies and health professionals
for responding to such a prominent challenge. Large-scale
clinical studies are also warranted to confirm and better
describe the extent of the NPSs phenomenon and to develop
effective strategies to clinically address it.
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